Clinical Study Results

This summary reports the results of only one study. Researchers must look at the results of many types of studies to understand if a study medication works, how it works, and if it is safe to prescribe to patients. The results of this study might be different than the results of other studies that the researchers review.

Sponsor:	Pfizer Inc.
Medicine(s) Studied:	PF-07284890
Protocol Number:	C4471002
Dates of Study:	17 June 2022 to 16 September 2022
Title of this Study:	A Study to Understand the Effect of Low-Fat and High-Fat Meals on the Medicine Called PF-07284890 in Healthy Adults [A Phase 1, Open-Label, Randomized, Single Dose, 2-Sequence, 3 Period Crossover Study to Evaluate the Effect of a Low-Fat and High-Fat Meal on the Relative Bioavailability of PF-07284890 in Healthy Adult Participants]
Date(s) of this Report:	23 August 2023

– Thank You –

If you participated in this study, Pfizer, the Sponsor, would like to thank you for your participation.

This summary will describe the study results. If you have any questions about the study or the results, please contact the doctor or staff at your study site.

Why was this study done?

What are BRAF V600-Mutated Advanced Solid Tumor Malignancies?

BRAF V600-mutated advanced solid tumor malignancies refer to a specific type of cancer that affects various tissues or organs in the body. It is called "advanced" because it has progressed beyond the initial stage and may have spread to other parts of the body.

In this particular type of cancer, there is a mutation (change) in a gene called BRAF, specifically at a location known as V600. This mutation alters the normal function of the gene and leads to uncontrolled cell growth and division, which is a hallmark of cancer.

Solid tumors are tumors that form in tissues such as the lungs, colon, skin, or thyroid, among others. Malignancies indicate that the tumors are cancerous and have the potential to invade nearby tissues or spread to distant parts of the body.

What is PF-07284890?

PF-07284890 is a tablet that is swallowed that researchers think may help treat people with certain cancerous solid tumors, with or without the cancer having spread to the brain. It is not currently approved for use by health authorities in the USA, where this study was held.

What was the purpose of this study?

The purpose of this study was to measure the amount of PF-07284890 in the participants' blood after a single, oral (by mouth), 200 mg dose taken after a low-fat meal and a high-fat meal, and without food.

This study did not test if PF-07284890 helps improve BRAF V600-mutated advanced solid tumor malignancies. The study was done in healthy participants.

Researchers wanted to know:

- **How did PF-07284890 act in the body of participants after a low-fat meal and a high-fat meal, compared to without food?**
- **What medical problems did participants have during the study?**

What happened during the study?

How was the study done?

Researchers tested PF-07284890 on a group of healthy participants to learn how PF-07284890 acted in the body.

All participants were “screened” to see if they would qualify to be in the study. Participants who qualified to be in the study were checked into the study unit the day before dosing (Day -1). Participants were required to stay in the study unit for up to 15 days and 14 nights.

The study consisted of 3 treatments:

- Treatment A: a single oral dose of PF-07284890 200 mg under fasted conditions (without food).
- Treatment B: a single oral dose of PF-07284890 200 mg after a low-fat meal.

- Treatment C: a single oral dose of PF-07284890 200 mg after a high-fat meal.

Two (2) treatment groups (6 participants in each group), shown in Figure 1, took Treatments A, B, and C across 3 study periods.

Researchers took samples of blood from participants during the study and measured the amount of PF-07284890 in the samples. Researchers also checked the participants' health during the study and asked them how they were feeling.

Researchers gave participants a follow-up phone call between 28 and 35 days from the final treatment to check how they were feeling.

The graphic below gives an overview of the study design.

Figure 1. How Was the Study Done?



Where did this study take place?

The Sponsor ran this study at 1 location in the USA.

When did this study take place?

The study began 17 June 2022 and ended 16 September 2022.

Who participated in this study?

The study included healthy adult participants who met the study criteria.

- A total of 11 men and 1 woman participated in the study
- All participants were between the ages of 20 and 65

Of the 12 participants who started the study, 10 finished the study.

Two (2) participants left before the study was over by their choice.

How long did the study last?

Study participants were in the study for up to about 3 months. The entire study took around 3 months to complete.

When the study ended in September 2022, the Sponsor began reviewing the information collected. The Sponsor then created a report of the results. This is a summary of that report.

What were the results of the study?

How did PF-07284890 act in the body of participants after a low-fat meal and a high-fat meal compared to without food?

To answer this question, researchers compared the levels of PF-07284890 in the blood of participants from Treatment B (PF-07284890 after a low-fat meal) and Treatment C (PF-07284890 after a high-fat meal) to Treatment A (PF-07284890 without food).

What was the amount of PF-07284890 in the blood after participants took 200 mg of PF-07284890 after a low-fat meal and a high-fat meal compared to without food?

The highest amount of PF-07284890 in the blood (known as C_{max}) after participants took 200 mg of PF-07284890 after a low-fat meal and a high-fat meal compared to without food is shown in Figure 2. The blue dot represents the value of the highest amount of PF-07284890 in the blood (C_{max}) after a low-fat meal and a high-fat meal compared to without food. A value more than 100% means that the C_{max} of PF-07284890 after a low-fat meal or a high-fat meal was higher than the C_{max} of PF-07284890 without food. Researchers considered the difference in the results as medium.

Figure 2. Ratio of PF-07284890 C_{max} After a Low-fat Meal and a High-fat Meal Compared to Without Food



What was the total amount of PF-07284890 from when PF-07284890 was taken to the time when the lowest amount of PF-07284890 was detected in the blood after a low-fat meal and a high-fat meal compared to without food?

The total amount of PF-07284890 from when PF-07284890 was taken to the time when the lowest amount was detected in the blood (known as AUC_{last}) after a low-fat meal and a high-fat meal compared to without food is shown in Figure 3. The blue dot represents the value of the total amount of PF-07284890 from when it was taken to the time when the lowest amount was detected in the blood (AUC_{last}) after a low-fat meal and a high-fat meal compared to without food. A value more than 100% means that the AUC_{last} of PF-07284890 after a low-fat meal or a high-fat meal was higher than the AUC_{last} of PF-07284890 without food. Researchers considered the difference in the results as relatively small.

Figure 3. Ratio of PF-07284890 AUC_{last} After a Low-fat Meal and a High-fat Meal Compared to Without Food



What was the estimated total amount of PF-07284890 in the blood from when PF-07284890 was taken until PF-07284890 was removed from the body after a low-fat meal and a high-fat meal compared to without food?

The estimated total amount of PF-07284890 in the blood from when PF-07284890 was taken until PF-07284890 was removed from the body (known as AUC_{inf}) is shown in Figure 4. The blue dot represents the value of the estimated total amount of PF-07284890 in the blood from when it was taken until it was removed from the body (AUC_{inf}) after a low-fat meal and a high-fat meal compared to without food. A value more than 100% means that the AUC_{inf} of PF-07284890 after a low-fat meal or a high-fat meal was higher than the AUC_{inf} of PF-07284890 without food. Researchers considered the difference in the results as relatively small.

Figure 4. Ratio of PF-07284890 AUC_{inf} After a Low-fat Meal and a High-fat Meal Compared to Without Food



Based on these results, the researchers have decided that the results are not likely due to chance. The study medication may act differently in the body when taken after a low-fat meal or a high-fat meal.

This does not mean that everyone in this study had these results. This is a summary of just some of the main results of this study. Other studies may have different results.

What medical problems did participants have during the study?

The researchers recorded any medical problems the participants had during the study. Participants could have had medical problems for reasons not related to the study medication (for example, caused by an unknown underlying disease or by chance). Or, medical problems could also have been caused by a study medication. Sometimes the cause of a medical problem is unknown. By comparing medical problems across many treatment groups in many studies, doctors try to understand what effects a study medication might have on a participant.

For Treatment A (PF-07284890 without food), 5 out of 12 (41.7%) participants had at least 1 medical problem. For Treatment B (PF-07284890 after a low-fat meal), 3 out of 12 (25.0%) participants had at least 1 medical problem. For Treatment C (PF-07284890 after a high-fat meal), 2 out of 10 (20.0%) participants had at least 1 medical problem. No participants left the study because of medical problems. All medical problems reported by participants are described below.

Below are instructions on how to read Table 1.

Instructions for Understanding Table 1.

- The **1st** column of Table 1 lists medical problems that were reported during the study. All medical problems reported by participants are listed.
- The **2nd** column tells how many of the 12 participants taking the study medication without food (Treatment A) reported each medical problem. Next to this number is the percentage of the 12 participants taking the study medication without food (Treatment A) who reported the medical problem.
- The **3rd** column tells how many of the 12 participants taking the study medication after a low-fat meal (Treatment B) reported each medical problem. Next to this number is the percentage of the 12 participants taking the study medication after a low-fat meal (Treatment B) who reported the medical problem.
- The **4th** column tells how many of the 10 participants taking the study medication after a high-fat meal (Treatment C) reported each medical problem. Next to this number is the percentage of the 10 participants taking the study medication after a high-fat meal (Treatment C) who reported the medical problem.
- Using these instructions, you can see that 0 out of the 12 (0%) participants taking the study medication in Treatment A reported stomach discomfort, 0 out of the 12 (0%) participants taking the study medication in Treatment B reported stomach discomfort, and 1 out of the 10 (10%) participants taking the study medication in Treatment C reported stomach discomfort.

Table 1. All medical problems reported by study participants			
Medical Problem	**Treatment A: PF-07284890 without food (12 Participants)**	**Treatment B: PF-07284890 after low-fat meal (12 Participants)**	**Treatment C: PF-07284890 after high-fat meal (10 Participants)**
Stomach discomfort	0 out of 12 participants (0%)	0 out of 12 participants (0%)	1 out of 10 participants (10%)
Upper stomach pain	1 out of 12 participants (8.3%)	0 out of 12 participants (0%)	0 out of 10 participants (0%)
Constipation	1 out of 12 participants (8.3%)	0 out of 12 participants (0%)	0 out of 10 participants (0%)
Throwing up	0 out of 12 participants (0%)	1 out of 12 participants (8.3%)	0 out of 10 participants (0%)
Feeling hot	0 out of 12 participants (0%)	1 out of 12 participants (8.3%)	0 out of 10 participants (0%)
Pain	0 out of 12 participants (0%)	0 out of 12 participants (0%)	1 out of 10 participants (10%)

Table 1. All medical problems reported by study participants			
Medical Problem	**Treatment A: PF-07284890 without food (12 Participants)**	**Treatment B: PF-07284890 after low-fat meal (12 Participants)**	**Treatment C: PF-07284890 after high-fat meal (10 Participants)**
Bruising where blood sample was taken	0 out of 12 participants (0%)	1 out of 12 participants (8.3%)	0 out of 10 participants (0%)
Common cold	0 out of 12 participants (0%)	1 out of 12 participants (8.3%)	0 out of 10 participants (0%)
High blood potassium	0 out of 12 participants (0%)	1 out of 12 participants (8.3%)	0 out of 10 participants (0%)
Joint pain	1 out of 12 participants (8.3%)	0 out of 12 participants (0%)	0 out of 10 participants (0%)
Muscle spasms	1 out of 12 participants (8.3%)	0 out of 12 participants (0%)	0 out of 10 participants (0%)
Neck pain	1 out of 12 participants (8.3%)	0 out of 12 participants (0%)	0 out of 10 participants (0%)

Table 1. All medical problems reported by study participants			
Medical Problem	**Treatment A: PF-07284890 without food (12 Participants)**	**Treatment B: PF-07284890 after low-fat meal (12 Participants)**	**Treatment C: PF-07284890 after high-fat meal (10 Participants)**
Headache	1 out of 12 participants (8.3%)	0 out of 12 participants (0%)	0 out of 10 participants (0%)
Tension headache	1 out of 12 participants (8.3%)	0 out of 12 participants (0%)	0 out of 10 participants (0%)
Hot flush	0 out of 12 participants (0%)	0 out of 12 participants (0%)	1 out of 10 participants (10%)

Did study participants have any serious medical problems?

A medical problem is considered “serious” when it is life-threatening, needs hospital care, or causes lasting problems.

No participants had serious medical problems. No participants died in the study.

Where can I learn more about this study?

If you have questions about the results of your study, please speak with the doctor or staff at your study site.

For more details on your study protocol, please visit:

www.pfizer.com/research/research_clinical_trials/trial_results	Use the protocol number **C4471002**

The full scientific report of this study is available online at:

www.clinicaltrials.gov	Use the study identifier **NCT05349864**

Please remember that researchers look at the results of many studies to find out which medicines can work and are safe for patients.

Again, if you participated in this study, **thank you** for volunteering. We do research to try to find the best ways to help patients, and you helped us to do that!